Malaysia Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Oct. 1, 2006 - 80 Pages

Table of Contents

Chapter 1 - Executive Summary

Malaysia Pharmaceuticals & Healthcare Industry SWOT

Malaysia Political SWOT

Malaysia Economic SWOT

Malaysia Business Environment SWOT

Chapter 2 - Malaysia: Business Environment Ranking

Table: Asia Business Environment Rankings

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Malaysia: Market Summary

Chapter 4 - Regulatory Regime

Recent Regulatory Developments

Intellectual Property Regime

Pricing & Reimbursement Developments

Industry Trends & Developments

Healthcare Sector

Table: HIV/AIDS Estimates (2003)

Pharmaceutical Sector

Pharmaceutical Demand Analysis

Domestic Company Activity

Foreign Company Developments

Regional and Global Co-operation

Biotechnology and Research

Chapter 5 - Industry Forecast Scenario

Overall Market Forecast

Table: Malaysian Drug Market Forecast Indicators

Key Growth Factors - Industry

Table: Malaysia Health Expenditure Forecast Indicators

Key Growth Factors - Macroeconomic

Table: GDP, Population and Output

Prescription Market Forecast

Table: Malaysia Prescription Drug Market Forecast Indicators

OTC Market Forecast

Table: Malaysia OTC Market Forecast Indicators

Generics and Branded Market Forecasts

Table: Malaysia Generics and Branded Drugs Market Forecast Indicators

Export/Import Forecasts

Table: Malaysia Pharmaceuticals Exports & Imports Forecasts

Other Healthcare Data Forecasts

Malaysia Pharmaceuticals & Healthcare Report Q3 2006

Table: Malaysia Healthcare Data Forecasts

Key Risks to BMI’s Forecast Scenario

Chapter 6 - Competitive Landscape

Table: Leading Firms By 2005 Sales

Chapter 7 - Company Profiles

GlaxoSmithKline

Pfizer

Novartis

Merck & Co

Sanofi-Aventis

Ranbaxy Malaysia

Eli Lilly Malaysia

Leading Indigenous Manufacturers

Pharmaniaga

Asia Pharmaceutical Products

Prime Pharmaceutical

Bumimedic

Chapter 8 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Abstract

The Malaysian pharmaceutical market, which has expanded at an annual rate of around 8% in the past 12-18 months, has a relatively high growth potential when compared to other similarly developed countries in the region. Prescription drugs account for around 75% of the total market value, with the segment likely to remain dominant in the future due to private sector support for established prescribing habits. Branded drugs, which presently represent over 70% of the total market, will continue to command the larger share in terms of value, as the demand for novel and life-style drugs increase. The situation will be reflected in the rising share of imports over time, which will further tip the trade balance in favour of foreign-made products.

BMI expects the Malaysian pharmaceutical market to grow 12% in US dollar terms in 2006. Market value is likely to exceed US$1.56bn in by 2010, boosted by changing demographics and rising healthcare expectations, which will boost demand for cardiovascular, CNS, metabolic and cancer drugs in particular. The treatment of infective diseases, especially hepatitis and HIV/AIDS, will necessitate supplies from abroad, while stimulating local research and development (R&D) activities in this direction. However, the country's continued failure to align its intellectual property (IP) regulations and enforcement with international standards will continue to hamper local activities of foreign companies, while simultaneously boosting the trade in fake drugs.

In regional terms, Malaysia will outperform a number of its immediate neighbours. The authorities' commitment to the development of a local pharmaceutical R&D base will attract foreign investment. However, strong regional competition in this field, especially in biotechnology, will have some detrimental effect on the rate of industry expansion.

Malaysian firms lack sufficient capacity to expand overseas, and will instead continue to focus on the local, mainly generic market. However, increased regional competition as well as the pressure on the authorities to comply with international IP standards will change the local landscape over the coming years, bringing a certain amount of industry consolidation. State-held Pharmanianga, presently the leading local player, will increase its efforts to secure a higher share of the generic market. In the meantime, multinational sector activity in the country will continue sporadically, dependent on prevailing regulatory and pricing conditions.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.